British Journal of Pharmacology · 2003 · 67 citations · 34 references
Life SciencesImmunologyPharmacologyEnzymologyInflammationInnate ImmunityChronic Obstructive Pulmonary DiseaseEnzyme InhibitionNeutrophil BiologyObstructive Lung DiseasePulmonary InflammationChronic Obstructive Pulmonary Disease PathophysiologyHeparin-protein InteractionsLow-molecular-weight Heparin TherapyNeutrophil AdhesionNeutrophil Physiology
1 Neutrophil-derived elastase is an enzyme implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). Heparin inhibits the enzymatic activity of elastase and here we provide evidence for the first time that heparin can inhibit the release of elastase from human neutrophils. 2 Unfractionated and low molecular weight heparins (UH and LMWH, 0.01-1000 U ml(-1)) and corresponding concentrations (0.06-6000 micro g ml(-1)) of nonanticoagulant O-desulphated heparin (ODH), dextran sulphate (DS) and nonsulphated poly-L-glutamic acid (PGA) were compared for their effects on both elastase release from and aggregation of neutrophils. 3 UH, ODH and LMWH inhibited (P<0.05) the homotypic aggregation of neutrophils, in response to both N-formyl-methionyl-leucyl-phenylalanine (fMLP, 10(-6) M) and platelet-activating factor (PAF, 10(-6) M), as well as elastase release in response to these stimuli, in the absence and presence of the priming agent tumour necrosis factor-alpha (TNF-alpha, 100 U ml(-1)). 4 DS inhibited elastase release under all the conditions of cellular activation tested (P<0.05) but had no effect on aggregation. PGA lacked efficacy in either assay, suggesting general sulphation to be important in both effects of heparin on neutrophil function and specific patterns of sulphation to be required for inhibition of aggregation. 5 Further investigation of the structural requirements for inhibition of elastase release confirmed the nonsulphated GAG hyaluronic acid and neutral dextran, respectively, to be without effect, whereas the IP(3) receptor antagonist 2-aminoethoxydiphenylborate (2-APB) mimicked the effects of heparin, itself an established IP(3) receptor antagonist, suggesting this to be a possible mechanism of action.
34
Vera M. Keatings, Paul Collins, Diane Scott et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 1.4K citations
CELL-SURFACE GLYCOSAMINOGLYCANS
Lena Kjellén, Staffan Johansson, Julie A. Robinson · Annual Review of Biochemistry · 1984 · 566 citations
Cell-Surface Glycosaminoglycans
Magnus Höök · Annual Review of Biochemistry · 1984 · 551 citations
Andrea Koenig, Karin E. Norgard-Sumnicht, Rorbert J. Linhardt et al. · Journal of Clinical Investigation · 1998 · 403 citations · Full text